Jonathan D. Cogen

Risk factors for lung function decline in a large cohort of young cystic fibrosis patients

Jonathan D. Cogen, Julia Emerson, Don B. Sanders et al. · Pediatric Pulmonology · 2015 · 124 citations

Medicine, Child Health, Pediatrics +17

Pulmonary Outcomes Associated with Long-Term Azithromycin Therapy in Cystic Fibrosis

Dave P. Nichols, Katherine Odem‐Davis, Jonathan D. Cogen et al. · American Journal of Respiratory and Critical Care Medicine · 2019 · 64 citations · Full text

Pharmacy, Pharmacotherapy, Antimicrobial Pharmacotherapy +13

Characterization of Inpatient Cystic Fibrosis Pulmonary Exacerbations

Jonathan D. Cogen, Assaf P. Oron, Ronald L. Gibson et al. · PEDIATRICS · 2017 · 63 citations · Full text

Medicine, Clinical Sciences, Pharmacotherapy +15

Chronic Azithromycin Use in Cystic Fibrosis and Risk of Treatment-Emergent Respiratory Pathogens

Jonathan D. Cogen, Frankline Onchiri, Julia Emerson et al. · Annals of the American Thoracic Society · 2018 · 44 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +17

The impact of elexacaftor/tezacaftor/ivacaftor on fat-soluble vitamin levels in people with cystic fibrosis

Georgene E. Hergenroeder, Anna Faino, Gracia Bridges et al. · Journal of Cystic Fibrosis · 2023 · 29 citations · Full text

Agriculture, Nutrition, Pharmacotherapy +14